Several gene expression-based methods have been developed for clinical use to predict the risk of distant recurrence, especially for the selection of patients benefiting from adjuvant chemotherapy among ER+/HER2- node-negative early breast cancer patients. Here, ERBB2 is linked to breast cancer.